Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...
emjreviews.com21h
New Strategy Enhances PD-1 Therapy in Treatment-Resistant Cancers
A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.
Science Daily7d
Innovative dual-target drug may lead to new investigational approach for breast cancer patients
Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...
Targeted Oncology3d
FDA Fast-Tracks IBI363 in Squamous NSCLC
The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...
Pharmabiz1d
Chugai obtains Japanese regulatory approval for Tecentriq for additional indication of alveolar soft part sarcoma, an ultra-rare disease
Chugai obtains Japanese regulatory approval for Tecentriq for additional indication of alveolar soft part sarcoma, an ultra-rare disease: Tokyo Friday, February 21, 2025, 10:00 Hr ...
The Pharma Letter1d
Chugai wins regulatory approval for Tecentriq for additional indication
Japanese drugmaker Chugai Pharmaceutical today announced gaining regulatory approval from the Ministry of Health, Labor and ...
Targeted Oncology1d
FDA Grants Breakthrough Therapy Status to Petosemtamab/Pembrolizumab in HNSCC
The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...
Pharmabiz2d
Merus’ petosemtamab receives US FDA breakthrough therapy designation for 1L PD-L1 positive head and neck squamous cell carcinoma
Utrecht, The Netherlands Thursday, February 20, 2025, 15:00 Hrs [IST] ...